PROTAC HSP90 degrader BP3 |
カタログ番号GC64825 |
PROTAC HSP90 デグレーダー BP3 は、CRBN 依存的に HSP90 を強力かつ選択的に分解します。プロタック HSP90 デグレーダー BP3 は、MCF-7 細胞の HSP90 タンパク質に対して一定の分解効果を示します (DC50=0.99 μM)。 PROTAC HSP90 デグレーダー BP3 は、乳がん細胞の増殖を抑制します。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2669072-88-0
Sample solution is provided at 25 µL, 10mM.
PROTAC HSP90 degrader BP3 is a potent and selective degradation of HSP90 in a CRBN-dependent fashion. PROTAC HSP90 degrader BP3 has a certain certain degradation effect on HSP90 protein in MCF-7 cells (DC50=0.99 µM). PROTAC HSP90 degrader BP3 inhibits the growth of breast cancer cell[1].
PROTAC HSP90 degrader BP3 (compound 16b) (72 h) inhibits the growth of breast cancer cells (IC50=0.63 µM in MCF-7 cells, IC50=3.53 µM in MDA-MB-231 cells, IC50=0.61 µM in 4T1 cells, IC50=2.95 µM in MDA-MB-468 cells)[1].PROTAC HSP90 degrader BP3 (2 µM; 6 h) shows degradation activity in the MCF-7 cells (DC50=0.99 µM)[1].
PROTAC HSP90 degrader BP3 (40 mg/kg; i.p., daily for 12 days) inhibits tumor growth and the tumor inhibition rate is 76.41%[1].
[1]. Liu Q, et al. Discovery of BP3 as an efficacious proteolysis targeting chimera (PROTAC) degrader of HSP90 for treating breast cancer. Eur J Med Chem. 2022, 228:114013.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *